palicalcitol

Phase 3Small molecule

XXiaoyan Jia

palicalcitol is one of 14 small molecule programs targeting Calcification. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CalcificationRecruiting

CalcificationPhase 3

Recruiting

Competition

Competitive Landscape

15 competitors in Calcification

#DrugCompanyPhaseTrials

Rocaltrol

Jazz Pharmaceuticals

Approved

1 2

Eliquis

Bristol-Myers Squibb

Approved

1 3

Zemplar

AbbVie

Approved

1 4

Xarelto

WWim Janssens

Approved

3 5

Coumadin

AAbbott

Approved

2 6

Fosamax

OOrganon and Co

Approved

2 7

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 8

Phoslo

VVifor Fresenius Medical Care Renal Pharma

Approved

2 9

palicalcitol

XXiaoyan Jia

Phase 3

1 10

Tums

Otsuka

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Calcification1 trial

Neutrophil Gelatinase-associated Lipocalin VS Vascular Calcification in Maintenance Hemodialysis Patients

Recruiting·XXiaoyan Jia·Phase 4·NCT05720273·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for palicalcitol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — palicalcitol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for palicalcitol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Xiaoyan Jia company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: XXiaoyan Jia

palicalcitol

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Calcification1 trial

References

Drug Info

Quick Facts

Related News